Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Chemical and Pharmaceutical Bulletin2019Vol. 67(8), pp. 824–838
Citations Over Time
Takanori Koike, Ryota Shiraki, Daisuke Sasuga, Mitsuru Hosaka, Tomoaki Kawano, Hiroki Fukudome, Kazuo KUROSAWA, Ayako Moritomo, Shinya Mimasu, Hirofumi Ishii, Seiji Yoshimura
Abstract
We synthesized and evaluated novel 5-[2-(thiophen-2-yl)propan-2-yl]-4H-1,2,4-triazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. Optimization of the thiophene ring and the substituents on the 1,2,4-triazole ring produced 3,4-dicyclopropyl-5-{2-[3-fluoro-5-(trifluoromethyl)thiophen-2-yl]propan-2-yl}-4H-1,2,4-triazole monohydrochloride (9a), which showed potent and selective inhibitory activity against human 11β-HSD1. Compound 9a was also metabolically stable against human and mouse liver microsomes. Oral administration of 9a to diabetic ob/ob mice lowered corticosterone levels in adipose tissue, and thereby reduced plasma glucose and insulin levels in a dose-dependent manner.
Related Papers
- → 11-β Hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity(2007)44 cited
- → Disengaging insulin from corticosterone: roles of each on energy intake and disposition(2009)40 cited
- → Effect of Fasting on Insulin Receptor Binding and Insulin Action in Different Human Subcutaneous Fat Depots*(1985)14 cited
- → Glucocorticoids and insulin: complex interaction on brown adipose tissue(1995)63 cited
- → Disparate effects of ACTH(1–24) and corticosterone on lipoprotein lipase in rat adipose tissue(1987)6 cited